B. Thompson Craig's most recent trade in Charles River Laboratories International Inc. was a trade of 2,076 Stock Options (Right to Buy) done . Disclosure was reported to the exchange on May 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Charles River Laboratories... | Craig B. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 2,076 | 2,076 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | Craig B. Thompson | Director | Grant, award, or other acquisition of securities at price $ 134.98 per share. | 21 May 2025 | 946 | 2,413 (0%) | 0% | 135.0 | 127,691 | Common Stock |
| Regeneron Pharmaceuticals,... | Craig B. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,958 | 1,958 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Craig B. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 166 | 620 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | Craig B. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 1,311 | 1,311 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | Craig B. Thompson | Director | Grant, award, or other acquisition of securities at price $ 228.41 per share. | 13 May 2024 | 559 | 1,467 (0%) | 0% | 228.4 | 127,681 | Common Stock |
| Regeneron Pharmaceuticals,... | B. Thompson Craig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,607 | 1,607 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Thompson B. Craig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 135 | 454 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | Craig B. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 1,669 | 1,669 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | Craig B. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 664 | 908 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | Craig B. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 592 | 592 | - | - | Stock Options (Right to Buy) | |
| Regeneron Pharmaceuticals,... | Craig B. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 477 | 477 | - | - | Non-Qualified Stock Option (right to buy) | |
| Charles River Laboratories... | Craig B. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 244 | 244 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharmaceuticals,... | Craig B. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 40 | 319 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharmaceuticals,... | Craig B. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 3,216 | 3,216 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Craig B. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 279 | 279 (0%) | 0% | 0 | Common Stock |